Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Stock Report

| More

Zydus announces second Phase 3 trial of Desidustat

Posted On: 2019-11-18 16:53:15

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced the second Phase III DREAM-D trials of Desidustat, an Investigational New Drug (IND) targeted at treating anemia in dialysis dependent CKD patients.

Chronic kidney disease is a serious medical condition which is an unmet healthcare need involving gradual loss of functioning of kidneys eventually leading to kidney failure. More than 200 million people worldwide are estimated to be living with chronic kidney disease. In a chronic kidney disease condition, the kidneys fail to produce EPO and this leads to anemia.

Desidustat is a novel, oral, HIF-PH inhibitor being developed for treating anemia in CKD patients. This Phase III DREAM-D study will be a multicenter (50-60 sites in India), randomized, active controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Epoetin for the treatment of anemia in patients with CKD who are on dialysis.

Speaking on the development, Mr. Pankaj R. Patel, Chairman, Zydus Group said, "Based on the positive proof-of-concept established in the Phase 2 clinical trials, we are committed to developing this novel drug, Desidustat that can benefit millions of CKD patients. We believe that Desidustat has the potential to provide an oral, safer alternative to the currently available therapy which is in an injectable form."

The primary end-point in Phase III DREAM-D study will be the efficacy of Desidustat tablet versus Epoetin alfa injection based on the change of hemoglobin (Hb) levels at 24 weeks. The secondary end-points will include number of hemoglobin (Hb) responders, time to achieve target range Hb level, percentage of time spent in target Hb range, serum hepcidin levels, serum potassium (K+) levels, vascular endothelial growth factor (VEGF) levels, lipid profile and lipoproteins.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.241.6 as compared to the previous close of Rs. 234.35. The total number of shares traded during the day was 112968 in over 2164 trades.

The stock hit an intraday high of Rs. 246.75 and intraday low of 236.65. The net turnover during the day was Rs. 27343676.

Source: Equity Bulls

Click here to send ur comments or to

Other Headlines:

Asian Oilfield Services Ltd secures Rs 640-crore seismic data acquisition work

Jubilant Industries subsidiary to recommence operations from May 15, 2020

Adani Transmission Limited receives LoI for Transmission Project in the State of Maharashtra

R Systems International Limited Board approves interim dividend of Rs. 1.50 for 2019

Prabhat Technologies launches parenteral control mobile application

Karnataka Bank launches KBL Xpress Car Loan

Aditya Vision Ltd opens 41st showroom

Hester Biosciences Ltd board to consider fund raising through issue of equity shares

Ashiana Housing Ltd announces conversion of EoI into booking for Phase 1 of 'Ashiana Aditya'

CARE A1+ rating assinged to Shree Cement's Commercial Paper

ABANS ENTERPRISES LTD announces resignation of CFO

RIL arm acquires 51.78% stake in Asteria

REC Ltd transfers stake in Rampur Sambhal Transco Limited to Powergrid

Wipro Promax Analytics Solutions recognised by Promotion Optimization Institute

Zensar participates in the 'Women in the Workplace 2019' report by McKinsey and LeanIn.Org

AU Bank announces the completion of Temasek's investment for 4.8% stake

BGR Energy Systems bags order from TANGEDCO

Acuite Ratings reaffirms A3+ rating for Dynacons' short term instruments

Premier Explosives Ltd receives license from Telangana Government

Kansai Nerolac dedicates an exclusive installation to Visakhapatnam under its 'Breathing City' initiative

TCS wins CII Industrial IP Award for Best Patents Portfolio

Metropolis Healthcare wins Patient Experience Team of the Year award

Mastek Limited sells its partial stake in Majesco to drive growth strategy

UFO Moviez Unveils New Brand Identity to Reinforce its Cinema Advertising Offering

Infosys Ltd updates on class action lawsuit

Magma Fincorp raises INR 350 Cr. from FMO - the Dutch Development Bank

Majesco Ltd to increase stake in Majesco USA to 74.6%

Smt. Usha Sangwan ceased to be nominee director of AXIS Bank Ltd

Vipin Sondhi appointed as MD & CEO of Ashok Leyland

Let us not forget our Fundamental duties in the clamour for Fundamental Rights

Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

IDEGO and EdgeVerve Join Hands to Drive RPA Adoption Across Latin America

Brickwork reaffirms ratings of SRG Housing Finance Limited

Sambhaav Media Ltd commences FM Radio Station at Bhaderwah (J&K) (94.3 MHz)

Embassy Group's HR Practices and Workplace Culture earns Top Rank in the Industry

Persistent Systems announces new leadership for unified Salesforce practice in Europe

Navin Fluorine International Ltd plans capex at Dahej, Gujarat

Datamatics to Strategically Divest its Stake in Cignex Datamatics Inc.

Aster DM Healthcare Ltd increases stake in Prerana Hospital Ltd to 86.99%

Kesar Enterprises Ltd accepts OTS with Allahabad Bank, UCO Bank

South African Depository Consolidates All Operations on to TCS BaNCS™ for Market Infrastructure

One of the leading Global Business Process Outsourcing Company Goes Live on Ramco

Wipro wins the '2019 SUSE Global System Integrator Partner of the Year' award

Infosys Awarded the 'Excellent Partner Award' by Mazda

Bank of Baroda allots 65,14,65,798 shares to Government of India

CreditAccess Grameen Wins the Prestigious 'Microfinance Organization of the Year' Award

INOX Leisure Limited commences operations of multiplex at Orion Mall, Gorakhpur

Wipro awarded Cloud and Infrastructure Transformation Partnership Contract by OlymPus

More than 50 percent of Enterprises look at Cloud Applications as a Foundation for Digital Transformation - Infosys Research

HT Media Ltd's Long term rating downgraded to 'CRISIL AA / Stable'

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019